# Valproate reactivates HTLV-1 tax and reduces ABCB1/MDR1 expression in PBMCs derived from ATLL patients

**Authors:** Célima Mourouvin, Julie Tram, Laetitia Marty, Anika Marie-Delcasse, Gildas Belrose, Aneta Pluta, Raymond Césaire, Phillipe Hélias, Véronique Baccini, Jean-Marie Peloponese

PMC · DOI: 10.3389/fonc.2026.1721313 · Frontiers in Oncology · 2026-03-12

## TL;DR

Valproate reactivates a virus-related protein in ATLL cells, reducing drug resistance and improving chemotherapy effectiveness.

## Contribution

Valproate reactivates Tax in ATLL cells, which lowers ABCB1 levels and restores chemosensitivity.

## Key findings

- ABCB1 is overexpressed in ATLL patient PBMCs compared to HTLV-1 carriers.
- Tax expression in T-cell lines reduces ABCB1 levels.
- Tax reactivation in ATLL cells restores sensitivity to chemotherapeutic drugs.

## Abstract

Chemoresistance remains a major obstacle to effective treatment and durable remission in leukemia patients. Although initial responses to chemotherapy are often favorable, relapse frequently occurs due to the emergence of drug-resistant malignant clones. Resistance mechanisms may be intrinsic or acquired and involve drug efflux, impaired apoptosis, enhanced DNA repair, epigenetic alterations, dysregulated signaling pathways, and microenvironmental interactions. A central mediator of multidrug resistance is the ATP-binding cassette (ABC) transporter family, particularly ABCB1 (also known as P-glycoprotein or MDR-1), which actively exports chemotherapeutic agents such as etoposide, doxorubicin, and vincristine, thereby reducing intracellular drug accumulation. Adult T-cell Leukemia/Lymphoma (ATLL), an aggressive malignancy caused by Human T-cell Leukemia Virus type 1 (HTLV-1), is characterized by poor prognosis and marked resistance to chemotherapy. Despite the recent approval of novel therapeutic agents, treatment outcomes remain unsatisfactory, largely due to both inherent and acquired chemoresistance. Overexpression of ABCB1 has been identified as a key mechanism contributing to multidrug resistance in ATLL. We compared the expression profiles of ABC transporter genes in CD8⁺-depleted peripheral blood mononuclear cells (PBMCs) from HTLV-1 asymptomatic carriers and patients with acute ATLL. To investigate the role of the viral transactivator Tax in regulating ABCB1 expression, we used HuT78 and JPX9 T-cell lines. Furthermore, Tax expression was reactivated in CD8⁺-depleted PBMCs from acute ATLL patients using valproic acid, and subsequent changes in ABCB1 expression and chemosensitivity to etoposide and doxorubicin were assessed. We found that ABCB1 expression was significantly upregulated in CD8⁺-depleted PBMCs from patients with acute ATLL compared to asymptomatic HTLV-1 carriers. In contrast, expression of the viral protein Tax in HuT78 and JPX9 cell lines resulted in decreased ABCB1 levels. Reactivation of Tax expression using valproic acid in primary ATLL samples confirmed that Tax downregulates ABCB1 expression. Importantly, Tax reactivation restored sensitivity of ATLL cells to chemotherapeutic agents, including etoposide and doxorubicin. Our findings identify ABCB1 overexpression as a major contributor to chemoresistance in acute ATLL and demonstrate that the viral protein Tax negatively regulates ABCB1 expression. These results suggest that reactivation of Tax may reduce drug efflux capacity and restore chemosensitivity in resistant ATLL cells. Collectively, this study provides a rationale for exploring a “Tax-based shock-andkill” strategy as a potential therapeutic approach to overcome chemoresistance in ATLL.

## Linked entities

- **Genes:** ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243], CNTN2 (contactin 2) [NCBI Gene 6900]
- **Proteins:** ABCB1 (ATP binding cassette subfamily B member 1), Mdr65 (Multi drug resistance 65), ABCB1 (ATP binding cassette subfamily B member 1), CNTN2 (contactin 2)
- **Chemicals:** valproic acid (PubChem CID 3121), etoposide (PubChem CID 36462), doxorubicin (PubChem CID 31703)
- **Diseases:** Adult T-cell Leukemia/Lymphoma (MONDO:0019471), ATLL (MONDO:0019471), leukemia (MONDO:0004355)

## Full-text entities

- **Genes:** ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, CNTN2 (contactin 2) [NCBI Gene 6900] {aka AXT, EPEO5, FAME5, TAG-1, TAX, TAX1}, CD8A (CD8 subunit alpha) [NCBI Gene 925] {aka CD8, CD8alpha, IMD116, Leu2, p32}
- **Diseases:** malignancy (MESH:D009369), multidrug resistance (MESH:D018088), ATLL (MESH:D015459), leukemia (MESH:D007938)
- **Chemicals:** etoposide (MESH:D005047), vincristine (MESH:D014750), doxorubicin (MESH:D004317), Valproate (MESH:D014635)
- **Species:** Human T-cell leukemia virus type I (no rank) [taxon 11908], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC13017922/full.md

## Figures

9 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13017922/full.md

## References

76 references — full list in the complete paper: https://tomesphere.com/paper/PMC13017922/full.md

---
Source: https://tomesphere.com/paper/PMC13017922